Tharun is a Chartered Financial Analyst from the CFA Institute, U.S. A graduate from Loyola College, Chennai, he started his career in Goldman Sachs at their Bangalore office. Prior to his current role at Proactive Investors, he worked as an equity analyst at a global research and analytics company in Mumbai, assisting institutional clients across Asia.
The capital raising has attracted a number of international institutional investors.
The company is currently fully funded in supporting all clinical research programs.
OA remains the most common form of joint disease globally, affecting over 30 million adults in the US alone.
In conjunction with the capital raise, Paradigm has revealed that it has successfully met the primary and secondary endpoints of its phase 2b trial in OA of the knee.
The medical technology company specialises in the development and marketing of premium non-invasive cardiovascular and pulmonary medical devices.
New Zealand listed shares in Synlait opened 12% lower this morning signalling a disappointing result.
The company has begun discussions with International key opinion leaders for mucopolysaccharidoses (MPS) clinical trial design and site selection.
The company said planned investment in the period and a softening of growth in China has had a short-term impact on profit growth.